[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586987":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":55,"collaborators":10,"id":59,"slug":10,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8,13,16,19,21],{"label":9,"type":10,"description":10,"interventionNames":11},"Right ventricular pacing group",null,[12],"Device: Pacemaker implantation",{"label":14,"type":10,"description":10,"interventionNames":15},"conduction system pacing group",[12],{"label":17,"type":10,"description":10,"interventionNames":18},"biventricular pacing group",[12],{"label":20,"type":10,"description":10,"interventionNames":10},"TR progression group",{"label":22,"type":10,"description":10,"interventionNames":10},"non-TR progression group",[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DEVICE","Pacemaker implantation","Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing",[9,17,14],[30],{"name":31,"affiliation":32,"role":33},"Haiyan Wang, MD","Shandong First Medical University","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","86-13583184107","wanghaiyan96@126.com",[40],{"facility":41,"status":42,"city":43,"state":10,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"The First Affiliated Hospital of Shandong First Medical University","RECRUITING","Jinan","250000","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.99722,36.66833,{"lat":51,"lon":50},[54],{"name":31,"role":36,"phone":37,"phoneExt":10,"email":38},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Haiyan Wang","Director","100586987",false,"NCT06922526","Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes","Predictors of Tricuspid Regurgitation Progression and Adverse Outcomes in Different Pacing Modes","Inclusion Criteria:\n\n1. Adult patients\n2. Patients with an implantable electronic heart device (CIEDs)\n3. The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025\n\nExclusion Criteria:\n\n1. Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation\n2. Patients with severe valvular heart disease, congenital heart disease, or arrhythmias\n3. Patients with single-chamber pacemakers or poor images","ALL","18 Years",{"count":68,"type":69},200,"ESTIMATED","OBSERVATIONAL","Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.\n\nThis study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.",[73,74],"Tricuspid Regurgitation","Pacemaker","2025-04-26",{"date":77,"type":78},"2025-04-30","ACTUAL",{"date":80,"type":69},"2025-04",{"date":82,"type":69},"2026-05",{"name":57,"class":6},1]